Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.

Chen-Hua LiuCheng-Yuan PengChun-Jen LiuChi-Yi ChenChing-Chu LoKuo-Chih TsengPei-Yuan SuWei-Yu KaoMing-Chang TsaiHung-Da TungHao-Tsai ChengFu-Jen LeeChia-Sheng HuangKe-Jhang HuangYu-Lueng ShihSheng-Shun YangJo-Hsuan WuHsueh-Chou LaiYu-Jen FangPo-Yueh ChenJow-Jyh HwangChi-Wei TsengWei-Wen SuChun-Chao ChangPei-Lun LeeJyh-Jou ChenChi-Yang ChangTsai-Yuan HsiehChung-Hsin ChangYi-Jie HuangJia-Horng Kao

Published in: Hepatology international (2023)

The study was not a drug trial. There was no need for clinical trial registration.

Keyphrases

hepatitis c virus infection
clinical trial
phase ii
phase iii
study protocol
hepatitis c virus
double blind
open label
randomized controlled trial
cross sectional
emergency department
dengue virus
electronic health record